FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080696087> ?p ?o ?g. }

• W2080696087 endingPage "6" @default.
• W2080696087 startingPage "1" @default.
• W2080696087 abstract "1. Altered vasoreactivity may contribute significantly to the pathogenesis of diabetic vascular complications. This study investigated the effect of (a) insulin-related diabetes, and (b) chronic in vivo administration of N(omega)-nitro-L-arginine ester (L-NAME), a nitric oxide (NO) synthase inhibitor, on mean arterial pressure and in vitro vascular reactivity to noradrenaline in mesenteric arterial bed preparations from spontaneously diabetic, insulin-dependent and treated BB rats, the best animal model of insulin-dependent mellitus (IDDM) currently available. Four groups of animals from the Edinburgh colony (BB/E) of spontaneous diabetic BB rats were studied: age-matched (mean +/- s.e. mean = 156 +/- 2d) non-diabetic (glycated haemoglobin = 3.8 +/- 0.1%) and insulin-treated diabetic (glycated haemoglobin = 6.2 +/- 0.5%; duration of diabetes = 56 +/- 4 d) groups were either L-NAME treated (oral dose = 27 +/- 1 mg kg-1 d-1; duration of treatment from 30 until 153 days of age) or untreated. Although our diabetic BB/E rats do not achieve overall normoglycaemia, individual adjustment of the daily insulin dose administered to every diabetic rat achieves better glycaemic control than previous groups studying altered vascular reactivity and endothelial dysfunction in this animal model of diabetes. 2. Mean arterial pressure (measured directly via indwelling carotid arterial cannulae) was not significantly different between non-diabetic (116 +/- 3 mmHg; n = 10) and diabetic (122 +/- 2 mmHg; n = 12) BB/E rats. L-NAME treatment significantly (P < 0.001) increased mean arterial pressure in both groups (165 +/- 6 mmHg; n = 9 and 142 +/- 4 mmHg; n = 6 respectively) but the degree of hypertension observed in L-NAME-treated diabetic rats was significantly (P < 0.01) attenuated compared to non-diabetic rats treated with L-NAME. 3. Mesenteric arterial bed preparations were cannulated under anesthesia, excised and intralumenally perfused ex vivo with noradrenaline (0.2-20 microM). Basal perfusion pressures were not significantly different in mesentery preparations from non-diabetic (27.0 +/- 2.6 mmHg) and diabetic (27.1 +/- 3.2 mmHg) BB/E rats. There was no significant difference in maximal response above basal perfusion pressure (MAX) or pEC50, defined as the negative log of the agonist concentration required to give 50% of the maximal response above basal perfusion pressure, to noradrenaline in untreated non-diabetic (166 +/- 7 mmHg and 5.74 +/- 0.05 respectively) and diabetic (170 +/- 11 mmHg and 5.59 +/- 0.05) BB/E rats. 4. In vivo treatment of non-diabetic and diabetic BB/E rats with L-NAME had no significant effect on basal perfusion pressure (25.9 +/- 4.3 mmHg and 28.5 +/- 3.9 mmHg respectively). L-NAME treatment in vivo increased (P < 0.001) MAX to noradrenaline of non-diabetic rats (224 +/- 8 mmHg) but did not affect the value for diabetic rats (178 +/- 14 mmHg). L-NAME treatment did not alter after the pEC50 values in either group (5.71 +/- 0.05 and 5.65 +/- 0.05). 5. Consistent with previous studies using vascular preparations from spontaneously diabetic BB rats, mesentery preparations from diabetic BB/E rats (n = 12) exhibited a significantly reduced vasodilator response to acetylcholine (F value = 4.4, P < 0.05) across the concentration range studied compared to non-diabetic BB/E rats (n = 12) although there was no significant difference in maximal relaxation (diabetic 53.1 +/- 4.3% vs non-diabetic 55.7 +/- 5.5%) or pEC50, (diabetic 6.92 +/- 0.25 vs non-diabetic 7.49 +/- 0.22). There was no significant (F value = 0.8, P > 0.1) difference in the response to GTN between preparations from non-diabetic and diabetic rats (maximal relaxation: 49.6 +/- 3.7% vs 48.5 +/- 4.3%; pEC50: 7.84 +/- 0.12 vs 7.89 +/- 0.22 respectively). 6. In conclusion, vascular responsiveness to noradrenaline is not impaired in spontaneously diabetic BB/E rats with significantly better glycaemic control than those used in previous studies. However, following chronic L-NAME treatment, diabetic BB/E rats exhibit attenuated hypertension and an absence of enhanced vascular responsiveness to noradrenaline in vitro compared to similarly treated non-diabetic rats. These results, together with the significantly impaired endothelium-dependent vasodilatation and unchanged endothelium-independent vasodilatation in vitro of preparations from diabetic BB/E rats, are consistent with the hypothesis that functional changes in the synthesis and metabolism of NO (rather than altered vascular responsiveness to NO) occur in diabetes. Our results indicate that good glycaemic control alone is insufficient to prevent these abnormalities in NO availability and further studies to characterize the origin of these changes are necessary." @default.
• W2080696087 created "2016-06-24" @default.
• W2080696087 creator A5000813082 @default.
• W2080696087 creator A5002516367 @default.
• W2080696087 creator A5051272103 @default.
• W2080696087 creator A5059195011 @default.
• W2080696087 creator A5070022992 @default.
• W2080696087 creator A5086972460 @default.
• W2080696087 creator A5089300509 @default.
• W2080696087 date "1997-01-01" @default.
• W2080696087 modified "2023-10-01" @default.
• W2080696087 title "In <i>vivo</i> and <i>in vitro</i> evidence of altered nitric oxide metabolism in the spontaneously diabetic, insulin-dependent BB/Edinburgh rat" @default.
• W2080696087 cites W1972038430 @default.
• W2080696087 cites W1980270769 @default.
• W2080696087 cites W1982065972 @default.
• W2080696087 cites W1989091901 @default.
• W2080696087 cites W1990800912 @default.
• W2080696087 cites W1991005356 @default.
• W2080696087 cites W2029371456 @default.
• W2080696087 cites W2030029892 @default.
• W2080696087 cites W2032167313 @default.
• W2080696087 cites W2032278674 @default.
• W2080696087 cites W2033525828 @default.
• W2080696087 cites W2042271610 @default.
• W2080696087 cites W2052009237 @default.
• W2080696087 cites W2059962850 @default.
• W2080696087 cites W2060481174 @default.
• W2080696087 cites W2073713671 @default.
• W2080696087 cites W2075100842 @default.
• W2080696087 cites W2077824574 @default.
• W2080696087 cites W2083001559 @default.
• W2080696087 cites W2085141749 @default.
• W2080696087 cites W2092349625 @default.
• W2080696087 cites W2093117735 @default.
• W2080696087 cites W2413340482 @default.
• W2080696087 cites W2419244580 @default.
• W2080696087 cites W2471727233 @default.
• W2080696087 cites W2769264260 @default.
• W2080696087 cites W4255164024 @default.
• W2080696087 doi "https://doi.org/10.1038/sj.bjp.0700862" @default.
• W2080696087 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1564340" @default.
• W2080696087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9117082" @default.
• W2080696087 hasPublicationYear "1997" @default.
• W2080696087 type Work @default.
• W2080696087 sameAs 2080696087 @default.
• W2080696087 citedByCount "19" @default.
• W2080696087 countsByYear W20806960872012 @default.
• W2080696087 countsByYear W20806960872013 @default.
• W2080696087 countsByYear W20806960872015 @default.
• W2080696087 crossrefType "journal-article" @default.
• W2080696087 hasAuthorship W2080696087A5000813082 @default.
• W2080696087 hasAuthorship W2080696087A5002516367 @default.
• W2080696087 hasAuthorship W2080696087A5051272103 @default.
• W2080696087 hasAuthorship W2080696087A5059195011 @default.
• W2080696087 hasAuthorship W2080696087A5070022992 @default.
• W2080696087 hasAuthorship W2080696087A5086972460 @default.
• W2080696087 hasAuthorship W2080696087A5089300509 @default.
• W2080696087 hasBestOaLocation W20806960872 @default.
• W2080696087 hasConcept C126322002 @default.
• W2080696087 hasConcept C134018914 @default.
• W2080696087 hasConcept C150903083 @default.
• W2080696087 hasConcept C207001950 @default.
• W2080696087 hasConcept C2776452961 @default.
• W2080696087 hasConcept C2777622882 @default.
• W2080696087 hasConcept C2777953023 @default.
• W2080696087 hasConcept C2779306644 @default.
• W2080696087 hasConcept C519581460 @default.
• W2080696087 hasConcept C555293320 @default.
• W2080696087 hasConcept C71924100 @default.
• W2080696087 hasConcept C84393581 @default.
• W2080696087 hasConcept C86803240 @default.
• W2080696087 hasConceptScore W2080696087C126322002 @default.
• W2080696087 hasConceptScore W2080696087C134018914 @default.
• W2080696087 hasConceptScore W2080696087C150903083 @default.
• W2080696087 hasConceptScore W2080696087C207001950 @default.
• W2080696087 hasConceptScore W2080696087C2776452961 @default.
• W2080696087 hasConceptScore W2080696087C2777622882 @default.
• W2080696087 hasConceptScore W2080696087C2777953023 @default.
• W2080696087 hasConceptScore W2080696087C2779306644 @default.
• W2080696087 hasConceptScore W2080696087C519581460 @default.
• W2080696087 hasConceptScore W2080696087C555293320 @default.
• W2080696087 hasConceptScore W2080696087C71924100 @default.
• W2080696087 hasConceptScore W2080696087C84393581 @default.
• W2080696087 hasConceptScore W2080696087C86803240 @default.
• W2080696087 hasIssue "1" @default.
• W2080696087 hasLocation W20806960871 @default.
• W2080696087 hasLocation W20806960872 @default.
• W2080696087 hasLocation W20806960873 @default.
• W2080696087 hasLocation W20806960874 @default.
• W2080696087 hasOpenAccess W2080696087 @default.
• W2080696087 hasPrimaryLocation W20806960871 @default.
• W2080696087 hasRelatedWork W1983641721 @default.
• W2080696087 hasRelatedWork W1995945960 @default.
• W2080696087 hasRelatedWork W2026226896 @default.
• W2080696087 hasRelatedWork W2032033851 @default.
• W2080696087 hasRelatedWork W2041678535 @default.
• W2080696087 hasRelatedWork W2066345847 @default.
• W2080696087 hasRelatedWork W2089387278 @default.

• next